EUCTR2005-003360-26-DE进行中（未招募）不适用
A randomized, multi-centre, double blind, parallel-group study assessing the analgesic efficacy and safety of different dosages of GRT0151Y bid compared to active comparator bid and placebo bid in subjects with chronic knee-joint osteoarthritis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Males or non-pregnant, non-lactating females. Female subjects of childbearing potential must use an acceptable method of contraception (i.e. hormonal method, IUD or double barrier) during the study period and have a negative urine pregnancy test (at enrolment and at day 1)
- •- 40-70 years of age
- •- No clinical relevant abnormalities of laboratory parameters taken at enrolment visit
- •- Subjects with a clinical diagnosis of osteoarthritis of the knee based on clinical ACR criteria and functional capacity class of I – III. Symptoms or radiographic criteria present for at least 3 months
- •- History of pain in the index joint > 6 months, treated with appropriate analgesics on at least 60 out of the last 90 days. Subjects who have previously used opioids must have experienced a positive therapeutic benefit from these opioids
- •- Increase in pain intensity in the index joint of at least one point reaching at least 5 points after wash-out period, using NRS
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Evidence or history of psychiatric illness, neurotic personality, severe senile dementia, Alzheimer’s disease, history of seizures or suicide risk, history of head trauma requiring evaluation by hospital based staff. Subjects with well-controlled depression may participate if they have unipolar disorder without manic episodes in personal or family history
- •- Poor medical status (e.g. NYHA class = 3; Child classification for hepatic
- •impairment > A (Pugh et al., 1973); decompensated chronic obstructive pulmonary disease) or, at the discretion of the investigator, clinical signs that raise concerns about subject’s suitability for the study
- •- Creatinine higher than 1.5x upper limit of normal range
- •- ALT and/or AST higher than 3x upper limit of normal range
- •- At enrolment ECG with findings which could impact any planned study procedure: e.g. marked repolarization abnormality (e.g. suspicious or definite congenital long QT syndrome) and/or QT values of: QTCB females = 450 msec, QTCB males = 430 msec, uncorrected QT = 500 msec
- •- Acute signs of referred pain, pain of meniscal or ligamental origin and the following pathogenic causes: congenital, direct traumatic, crystal-induced, metabolic, infectious and autoimmune. Clinical diagnosis of fibromyalgia according to ACR-definition
- •- Previous history of replacement-surgery at the index joint or the subject is expected to require surgical intervention on the index joint
- •- Intraarticular administration (index joint) of depot-steroids within three months or viscous supplements within six months prior to enrolment
- •- Start of physiotherapy and/or use of orthopedic devices = 4 weeks prior to enrolment
- •- Definite or suspected allergy or hypersensitivity to drugs having a similar mechanism of action as investigational medicinal product. Known contraindications/ hypersensitivity to opiods, oxycodone, or paracetamol/ acetaminophen
- •- Use of fentanyl transdermal system, buprenorphin sublingual or transdermal system, = 7 days prior to enrolment
- •- Chronic (= 2 weeks) oral intake of corticosteroids less than two weeks prior to enrolment
- •- Use of antiparkinsonian drugs, MAO-inhibitors, SSRIs, SNRIs, neuroleptics or other drugs that may lower the seizure threshold, = 4 weeks prior to enrolment
- •- Intake of adjuvant analgesics (e.g. antidepressants, anticonvulsants, muscle relaxants) and of disease modifying drugs (e.g. glucosamines) if not on a stable dose since at least 28 days prior to enrolment
研究者
相似试验
已完成
3 期
Ayurveda product clinical trial on overweight subjectsCTRI/2020/09/027807IndusViva HealthSciences Pvt Ltd70
招募中
3 期
Evaluation of efficacy, safety and immunogenicity of Lupins Denosumab compared to Prolia in postmenopausal women with osteoporosis.OsteoporosisJPRN-jRCT2031230117Sakine Michitoshi400
进行中（未招募）
3 期
A Study to assess effectiveness and safety of Lupin’s Denosumab (IRO2201A/LUBT014) compared to Prolia®CTRI/2023/09/057671upin Limited
进行中（未招募）
不适用
A randomized, multicenter, double-blind, parallel study to compare the efficacy and safety profile of RGH-507 (tolperisone-containing) gel versus a ketoprofen-containing gel in the treatment of patients with soft tissue injuries.acute soft tissue injury minor traumatism (such as: sprain, strain, dislocation,...etc.) or contusionMedDRA version: 12.0Level: PTClassification code 10041291Term: Soft tissue injuryEUCTR2009-013864-37-HUGedeon Richter Plc.300
进行中（未招募）
不适用
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg aloneHypertensionEUCTR2006-004586-34-FRovartis Pharma Services AG1,018